C ardiac imaging using Doppler-echocardiography (D-E) provides information on patients with left ventricular systolic dysfunction (LVSD) that goes beyond assessing LV ejection fraction (LVEF). Such imaging makes it possible to assess systolic and diastolic LV function and remodeling, the presence and severity of functional mitral regurgitation (FMR), and pulmonary hypertension (PH). All of these measures of LV remodeling can also be quantified during the same examination. However, the clinical significance and link to outcome of each individual measure are uncertain and difficult to extricate because of the frequent parallel development of multiple cardiac alterations. PH is of particular importance to analyze because it is a known complication of LVSD and can be measured and followed in serial examinations. 1, 2 However, the assessment of PH in the setting of LVSD is not a specified recommendation as either a primary or follow-up measurement by current American College of Cardiology Foundation/American Heart Association, Heart Failure Society of America, or European Society of Cardiology heart failure (HF) practice guidelines. [3] [4] [5] Although it has been asserted that PH is associated with worsening outcomes, [6] [7] [8] [9] [10] [11] [12] [13] the available evidence has not been considered compelling because PH is the physiological consequence of multiple other hemodynamic alterations that include not only LVSD but also the severity of FMR 14 and LV diastolic dysfunction (LVDD), 15 both of which are important determinants of survival in LVSD. Furthermore, PH is often thought to be associated with severe HF symptoms, which are recognized as markers of outcome with LVSD. 3, 16 Therefore, in analyzing the value of D-E imaging, specifically in assessing the independent prognostic role of imaging-defined PH, it is uncertain whether it has incremental value to symptoms and other markers of LV remodeling. The consequences of establishing the independent prognostic role of imaging-defined PH are significant in terms of testing, guideline recommendations, and novel-targeted therapy. Reports focusing on the role of PH have been performed almost exclusively in patients with overt congestive HF or after a hospitalization for an acute event, [7] [8] [9] [10] [17] [18] [19] and where adjustments for LVSD and markers of LV remodeling were partially or often qualitatively acquired. Thus, the PH question remains unanswered, particularly with regard to the vast majority of LVSD outpatients without severe HF and accounting for quantified background descriptors of LV remodeling, such as FMR and LVDD. 12, 15, 20, 21 In addressing these complex issues, our clinical practice with large outpatient involvement and methodical quantitative approach to LVSD characterization, particularly FMR, provides the opportunity to assess the independent role of PH in patients with LVSD in a comprehensive design carefully. Therefore, the aim of this study was to compare survival after diagnosis of LVSD between patients with and without PH documented by D-E imaging with matching of these groups for major markers of outcome (age, sex, LVEF, severity of FMR) and to examine overall and in subsets of patients the hypothesis that PH is, in and of itself, an independent factor for all-cause mortality and not merely a colinear variable of LVSD.
Methods
Patients undergoing comprehensive D-E evaluation as part of their outpatient clinical cardiovascular assessment at the Mayo Clinic, Rochester, during the period of August 1, 2001 , to December 31, 2004 , were retrospectively analyzed. Inclusion criteria were the following: age >18 years, presence of LV systolic dysfunction defined by an LVEF≤40%, pulmonary systolic pressure (PSP) measurable by D-E using tricuspid regurgitation velocity, normal right ventricular systolic function as determined by measurement of tricuspid annular plane systolic excursion (normal range 17-20 mm) or tricuspid annular systolic tissue Doppler imaging 22 (normal >12 cm/s), and quantitative assessment of severity of FMR. Exclusion criteria were atrial fibrillation; organic mitral, tricuspid, or aortic valvular disease other than mild, or status after mitral valve replacement/repair or any prosthetic valve; infiltrative, constrictive, or hypertrophic cardiomyopathy; myocardial infarction within 6 months of index D-E evaluation; chronic obstructive pulmonary disease other than mild; congenital heart disease; tachycardia-related dysrhythmias; primary pulmonary arterial hypertension or pulmonary thromboembolic disease; history of chest radiation; and collagen vascular diseases or status after cardiac or lung transplantation. Clinical data, including symptoms, were obtained by programmed electronic medical records abstraction. Where data were not electronically available or incomplete, patient records were manually reviewed and data abstracted. Patient survival/all-cause mortality status was confirmed through January 1, 2012 (censor date), using Mayo Clinic Rochester electronic medical records, Olmsted County, MN, medical record linkage system (Rochester Epidemiology Project), and the Social Security Mortality Index. 
Doppler-Echocardiography
A comprehensive 2-dimensional and D-E examination was performed on all patients. 23, 24 LV size and function (LVEF) were derived by standard methods according to American Society of Echocardiography recommendations. 25 Continuous wave Doppler was used to assess maximal tricuspid regurgitation flow velocity to estimate the systolic pressure gradient between the right ventricle and the right atrium. Right ventricular systolic pressure was then calculated by adding estimated right atrial pressure. 26 This derived pressure was considered to be identical to PSP after demonstrating the absence of any abnormality of the pulmonary or tricuspid valve. The threshold definition of PH was an estimated PSP≥45 mm Hg. 11, 15, 20, 27 Quantification of FMR by effective regurgitant orifice area, measures of LV diastolic function (mitral E/e′ ratio, mitral valve deceleration time), cardiac index, and left atrial volume were undertaken as previously described.
15

Patient Matching Process
The initial data set consisted of 1174 patients with PSP≥45 mm Hg and 1929 patients with PSP<45 mm Hg, all meeting inclusion/exclusion criteria. To control for the imbalances of the 2 groups with regard to the presence and severity of FMR and comorbidities and for the benefit of cost control, subjects with PSP<45 mm Hg were matched to subjects with PSP≥45 mm Hg by creating sampling bins based on age (±3 years), sex, LVEF (±5%), FMR presence and severity, and year of index D-E examination. FMR was matched qualitatively (none-trivial, mild, moderate, or moderate-severe), and the quantitative strata of effective regurgitant orifice area and regurgitant volume measurements were similar in both subgroups as expected by the matching process. Within each sampling bin, an equal number of patients with and without PH were selected randomly, thus guaranteeing a frequency-matched cohort design. This procedure resulted in matching 1384 patients (692 in each group with and without PH) of the 3106 eligible patients.
Statistical Analyses
Data are presented as mean±SD or median with 25th and 75th percentiles for continuous data and as number and percentage for categorical data. To assess univariate differences, baseline and hemodynamic variables were compared by Student t tests or the nonparametric Wilcoxon signed-rant test when normality assumptions were not achieved. Categorical variables were tested for significance using a likelihood ratio χ 2 test. Linear regression analyses were used to assess associations between hemodynamic variables. Logistics regression analysis was performed to identify variables associated with the presence of correlate PH. Results are presented as odds ratios with P values; the odds ratios for continuous variables are the odds of spanning the range of the data. Survival was estimated using the KaplanMeier method with log-rank analysis used to compare the end point of all-cause mortality among subgroups. Mortality was evaluated in univariate and multivariate analyses using Cox proportional hazards models adjusting for relevant baseline differences that would affect mortality. Risk factors were significantly different between the hemodynamic groups at baseline, and factors that were clinically important were evaluated for these models. Cox proportional hazards regression was used to assess the contribution to unadjusted hazards analysis for mortality based on hemodynamic parameters using different hemodynamic variables to define abnormality. Results are presented as forest plot with corresponding P values. The association of relative risk of death using hemodynamic parameters as continuous variables was investigated using penalized splines (p-splines) within the Cox model. 28 The number of knots used for the smoothing spline was determined by the set defaults of the package and resulted in 12 equally spaced interior knots with increments of 10.74. With this approach, we were able to verify the proportional hazards assumption and robustly estimate the functional form of each variable with the risk of death. Figures are presented using a log scale (Y-axis) because this is the natural scale for testing the linearity of the hazard function. The Charlson index summating the patient's individual comorbidities, including specific LVSD-related morbidity, was calculated to aid in the characterization of the cohort. 29 Statistical testing was 2-tailed; P values <0.05 were accepted as statistically significant. Analyses were performed using JMP version 7 software and R version 2.14.
Results
Clinical and Hemodynamic Characteristics
A total of 1384 patients with and without PH met matching criteria according to age, sex, LVEF, and FMR (presence and distribution of severity of FMR). Patient demographic and clinical characteristics are shown for the matched cohorts in Table 1 . The median PSP in the cohort with PH was 54 mm Hg (25th to 75th percentile of 48-62 mm Hg) and 32 mm Hg (28-37 mm Hg) in patients without PH. The 2 cohorts were well matched with the exception of a higher prevalence of diabetes mellitus in patients with PH and associated greater diabetic medication use. Other medication usage was well distributed between groups. The patients with PH were more often symptomatic. The comorbidity burden was moderately high in both cohorts, with an average Charlson index of 3 without significant differences between groups. Table 2 shows the D-E features of the matched cohorts. Systolic blood pressure and heart rate were statistically higher in patients with PH, but the differences were not clinically significant. Doppler-derived hemodynamic parameters of LV diastolic function (E/e′ ratio and mitral valve deceleration time) were more often abnormal in patients with PH, but such a link is expected in view of the association between LVDD and PH we and others have previously reported. 13, 15, 16, 30, 31 Left atrial volume, also a marker of diastolic dysfunction, 32 was higher in patients with PH.
Survival After Diagnosis
The median follow-up time for the combined cohorts was 8.9 years (limits, 1 month to 11.7 years), and during the study 885 patients died (64%). Of these, 478 had PH and 407 were without PH. Figure 1 shows the Kaplan-Meier survival estimates for the matched cohorts with PSP≥45 mm Hg, demonstrating a significantly poorer outcome than PSP<45 mm Hg. Although PSP is most commonly analyzed as a dichotomous variable clinically, we also evaluated this parameter as a continuous variable. Figure 2 (cubic spline analysis) shows the relationship where progressively higher PSP is associated with a progressively higher risk for all-cause mortality. The threshold at which the relative mortality risk crosses unity ≈45 to 50 mm Hg with a linear increase in risk ≤60 mm Hg where a steeper rise in risk is demonstrated.
Cox proportional hazards regression analysis was used to evaluate the association between PSP and all-cause mortality univariately and with adjustment for baseline characteristics of age, sex, FMR, LVEF, Charlson index, symptoms, and LVDD (Table 3 ). These variables were selected for their 
Subgroup Analyses
Separate subgroup analyses by PSP<45 and ≥45 mm Hg for common variables of risk were also undertaken to assess their individual effect on mortality risk. Age above and below median for the cohort (<73 and ≥73 years), sex, presence of symptoms, Charlson index, absence (none-trivial) versus presence of FMR, and presence of diabetes mellitus at the time of index D-E evaluation were evaluated (Figure 3) . Older age was associated with increased risk of all-cause mortality, but the presence of PH superimposed a separate significant effect on risk, particularly high in the younger patients (age <73 years: HR, 1.64; 95% CL, demonstrated for the Charlson index and FMR. Irrespective of the influence of these factors on outcome, the presence of PH retained an independent effect on mortality. The only baseline characteristic potentially affecting the effect of PH was diabetes mellitus. In patients with non-diabetes mellitus PH had a clear link to excess mortality, whereas in patients with diabetes mellitus the effect did not reach significance. These findings suggest that the association of PH to excess mortality is not the result of random association and is demonstrated in nearly all subgroups similarly to the observation that it demonstrated independently of all adjustments.
Discussion
The findings of this study address a knowledge gap by demonstrating that imaging-defined PH complicating LVSD, distinct from symptoms, is a powerful and independent marker of all-cause mortality. Furthermore, the link between PH and outcomes is not as a surrogate coupled with associated clinical predictors, comorbidities, or even the extent of symptoms commonly associated with LVSD. This critical finding is to be viewed in light of the fact that in the current HF practice guidelines, [3] [4] [5] [6] the assessment for PH is not listed among specifically recommended D-E measurements, and PH is not addressed as a marker of worse outcome or a target for therapy.
Our matching analysis addressed common predictors of outcome (age, sex, LVEF, and FMR severity), and while not among the matching characteristics, important confounders, such as therapy and comorbidities, also proved to be similarly distributed in the cohorts with and without PH. This contributed to minimizing patient heterogeneity and selection bias that limits interpretation of previous studies. [7] [8] [9] [10] 18, 19 In addition, the large number of events in the present study permitted defining the role of PH in a number of subgroups not previously represented in such analyses. Although in patients with diabetes mellitus, PH association to survival did not reach significance, despite a trend, all other subgroups (young and old, men and women, with and without FMR, with and without symptoms, and with and without large comorbidity burden) showed significant links between PH and survival independent of these confounders. Thus, the association of PH to survival after diagnosis independent of all markers of outcome, including symptoms, and independent of factors that initiate the pulmonary pressure elevation (FMR and LVDD) suggests that PH is important in and of itself. Therefore, measurements of PSP should be considered routine in patients with LVSD, and the attention given to this association should be sustained to minimize future adverse events. Physiological studies to gain insights into the development of PH and clinical trials of novel PH-specific treatments, in addition to current treatment regimens, should be strongly considered as priorities.
Mechanisms of PH in LVSD
We have previously reported on the contribution of LVDD as a significant predictor for the presence of PH in clinically stable patients. 15 The current analysis emphasizes that even though parameters of diastolic dysfunction and other clinical variables are highly predictive of PH, PH is a distinct risk factor for mortality independent of LVDD or severity of LVSD. The lack of association of PH with the severity of LVSD (low LVEF) has been previously reported, 7, [9] [10] [11] [12] but our findings show that PH confers a severe influence on LVSD by its independent association to poor survival after diagnosis. This finding is also independent of the presence and severity of FMR, which is by itself linked to outcome. 18 By quantifying the FMR, which is poorly assessed by standard qualitative methods, we ensured that through the matching process patients with and without PH had similar degrees of FMR so that we could ascertain for the first time that the PH link to morality is not a surrogate for FMR. Furthermore, our subgroup analysis, which could not be performed in previous studies because of lack of FMR ascertainment, [7] [8] [9] 33 shows that PH is equally predictive of excess mortality with or without FMR, confirming the independent role of PH in predicting survival. Similarly, although an independent link between LVDD and mortality is not entirely established, by obtaining quantitative measures of LVDD, we were also able for the first time to demonstrate that PH is not a surrogate of LVDD. Thus, our comprehensive quantitative imaging assessment allows for the conclusion that PH is truly an independent marker of excess mortality.
Prognostic Significance and Clinical Implications of PH in LVSD
Although age, comorbidities, symptoms, FMR, and to some extent sex negatively influence outcomes and likely dilute the overall effect of PH on mortality, PH imposes a singular contribution to worsening outcome. In addition, as demonstrated in our analysis, even in those patients without symptoms or FMR, the identification of PH was associated with increased mortality risk. The development of PH in these patients with no or few symptoms or physical findings arguably puts these patients at high risk because of the absence of risk markers and, therefore, a possible reduced vigilance as to the presence of PH. This emphasizes the need for a focused imaging and also therapy approach in patients with evidence of LVSD. PSP should be systematically evaluated in all patients with LVSD, and patients should also be followed closely to identify the development of PH as a marker of disease progression that initially may be clinically silent. Furthermore, this should support a need for more intense and novel treatments to reduce the risk associated with PH in LVSD in otherwise stable outpatients without recent events.
Limitations
In interpreting these data, the retrospective nature of the study needs to be considered. Pulmonary pressures were calculated from D-E-derived data, which reflect current clinical practice; the noninvasive methodology has been well established for the assessment of PSP. 1, 2, 25, [34] [35] [36] The matched nature of the study design and patient cohort limits heterogeneity and accounts for many, if not all, commonly associated clinical variables that otherwise confound data interpretation. It should be noted that not all eligible patients were included in the final analysis as a result of the matching process (1384 patients included of 3106 eligible). Also, patients with right ventricular systolic dysfunction were excluded, and, therefore, the results do not apply to patients with combined LV and RV systolic dysfunction. However, the results of this study reflect observations from standard clinical outpatient practice with a design to control for the confounding influence of common clinical variables on the interpretation of the effect of PH with LVSD.
Conclusions
In this large cohort of matched ambulatory outpatients with LVSD, with and without PH, PH was demonstrated to be a powerful factor contributing to mortality independent from the severity of diastolic or systolic LV dysfunction, presence of FMR, and clinical variables of age or comorbidities. Notable from this analysis is the observation that the absence of symptoms or FMR in outpatients without recent hospitalizations or acute episodes of decompensation did not mitigate the effect of PH on poor outcomes. These findings, if confirmed in prospective analyses, support the benefit of routine PH-focused D-E imaging evaluations in patients with LVSD and PH-directed therapy aimed at preventing the clinical progression and excess mortality associated with LVSD.
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